Ginkgo may modestly increase bleeding risk with warfarin, aspirin, or clopidogrel. Evidence is mixed but precaution is warranted.
What's happening
Ginkgo biloba extracts contain ginkgolide B, a platelet-activating factor (PAF) antagonist that can inhibit platelet aggregation in vitro. The biochemical effect is real; the clinical magnitude is contested. The largest observational study (Stoddard 2015, VA, N=807,399 warfarin patients) found a hazard ratio of 1.38 (95% CI 1.20-1.58, p<0.001) for bleeding adverse events with concurrent ginkgo + warfarin. A 2025 observational study (Mai et al, N=2,647 prescriptions) did NOT find a warfarin signal but did find modest bleeding associations with ginkgo + aspirin (OR 1.12) and ginkgo + clopidogrel (OR 1.10). A randomized controlled trial (Gardner 2007, N=55 older cardiovascular patients) testing EGb 761 300 mg/day plus aspirin 325 mg/day for 4 weeks found no effect on platelet function and no bleeding events. The most comprehensive systematic review (Bone 2008) concluded that controlled studies consistently show no significant hemostasis effect and that published case reports are low quality. The pattern — real population signal, negative RCTs — is consistent with confounding by indication, but the possibility of real modest harm cannot be excluded. Patients scheduled for surgery should stop ginkgo 5-7 days in advance per standard pre-anesthesia guidance. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) have not been directly studied; class-based caution applies.
Recommendation
Do not self-start ginkgo if you are on warfarin, aspirin, clopidogrel, or any anticoagulant/antiplatelet. Consult the clinician who manages your blood thinner first. If you are already taking both, do not stop abruptly — ask your prescriber about tapering and monitoring. Watch for unusual bruising, prolonged bleeding from minor cuts, gum bleeding, nosebleeds, or dark stools. Stop ginkgo 5-7 days before any scheduled surgery or neuraxial procedure.
Timing
Timing-based separation does not mitigate this interaction. Monitoring (INR for warfarin patients, clinical symptoms for antiplatelet patients) is the relevant mitigation.
Sources
— PMID:26958227 — Stoddard GJ et al. Ginkgo and Warfarin Interaction in a Large Veterans Administration Population. AMIA Annu Symp Proc 2015.
— DOI:10.1371/journal.pone.0321804 — Mai et al. Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles. PLoS ONE 2025.
— PMID:17982321 — Gardner CD et al. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation. Blood Coagul Fibrinolysis 2007.
— PMID:18214851 — Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence? Mol Nutr Food Res 2008.
How it works
Ginkgo biloba extracts contain ginkgolide B, a platelet-activating factor (PAF) antagonist that can inhibit platelet aggregation in vitro. The biochemical effect is real; the clinical magnitude is contested. The largest observational study (Stoddard 2015, N=807,399 VA warfarin patients) found HR 1.38 (95% CI 1.20-1.58, p<0.001) for bleeding. Controlled trials at testable doses have been largely null.
Who should be careful
Patients on warfarin — largest observational signal (HR 1.38); highest concern given therapeutic INR management.
Patients on aspirin or clopidogrel — modest observational signal; RCT evidence reassuring at typical doses.
Patients on DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — not directly studied; class caution applies.
Patients scheduled for surgery or neuraxial anesthesia — stop ginkgo 5-7 days before the procedure.
What we don't know
No adequately powered RCT of ginkgo + warfarin with a clinical bleeding endpoint exists. Dose-response curve is not characterized. Whether standardized EGb 761 vs other extracts differ in risk is plausible but not proven. DOACs have not been directly studied.
Why this severity
WARNING, not DANGER: the mechanism is real but clinical magnitude is modest (HR/OR 1.10-1.38) and not reliably reproduced in controlled trials. The precautionary WARNING honestly reflects the evidence split.
Evidence quality (GRADE): low
Frequently Asked Questions
Can I take blood thinners and ginkgo biloba together?
Ginkgo may modestly increase bleeding risk with warfarin, aspirin, or clopidogrel. Evidence is mixed but precaution is warranted.. Do not self-start ginkgo if you are on warfarin, aspirin, clopidogrel, or any anticoagulant/antiplatelet. Consult the clinician who manages your blood thinner first. If you are already taking both, do not stop abruptly — ask your prescriber about tapering and monitoring. Watch for unusual bruising, prolonged bleeding from minor cuts, gum bleeding, nosebleeds, or dark stools. Stop ginkgo 5-7 days before any scheduled surgery or neuraxial procedure.
How should I time blood thinners and ginkgo biloba?
Timing-based separation does not mitigate this interaction. Monitoring (INR for warfarin patients, clinical symptoms for antiplatelet patients) is the relevant mitigation.
Is this interaction dangerous?
This interaction is rated “Warning” by Formulate. Ginkgo biloba extracts contain ginkgolide B, a platelet-activating factor (PAF) antagonist that can inhibit platelet aggregation in vitro. The biochemical effect is real; the clinical magnitude is contested. The largest observational study (Stoddard 2015, VA, N=807,399 warfarin patients) found a hazard ratio of 1.38 (95% CI 1.20-1.58, p<0.001) for bleeding adverse events with concurrent ginkgo + warfarin. A 2025 observational study (Mai et al, N=2,647 prescriptions) did NOT find a warfarin signal but did find modest bleeding associations with ginkgo + aspirin (OR 1.12) and ginkgo + clopidogrel (OR 1.10). A randomized controlled trial (Gardner 2007, N=55 older cardiovascular patients) testing EGb 761 300 mg/day plus aspirin 325 mg/day for 4 weeks found no effect on platelet function and no bleeding events. The most comprehensive systematic review (Bone 2008) concluded that controlled studies consistently show no significant hemostasis effect and that published case reports are low quality. The pattern — real population signal, negative RCTs — is consistent with confounding by indication, but the possibility of real modest harm cannot be excluded. Patients scheduled for surgery should stop ginkgo 5-7 days in advance per standard pre-anesthesia guidance. DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) have not been directly studied; class-based caution applies.
Studies from our registry that mention both blood thinners and ginkgo biloba. Each links to the primary source and the other Formulate pages citing it.
The free checker lets you add any combination of supplements and medications at once. The free web app goes further — every stack change surfaces interaction alerts automatically.